Cemiplimab removed from reimbursable drugs in France
Authors:
- 1 May 2021
- journal article
- letter
- Published by Elsevier in European Journal of Cancer
- Vol. 149, 11-13
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- 1086P Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experienceAnnals of Oncology, 2020
- Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosingJournal for ImmunoTherapy of Cancer, 2020
- European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. TreatmentEuropean Journal of Cancer, 2020
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trialThe Lancet Oncology, 2020
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2018
- Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of the DeCOGEuropean Journal of Cancer, 2018
- Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic ReviewDermatologic Surgery, 2017